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ABSTRACT 
Myeloproliferative neoplasms (MPN), Essential Thrombocythemia (ET), Polycythemia 
Vera (PV) and primary myelofibrosis (PMF), are clonal disorders of the hematopoietic 
stem cell. In the recent years, somatic mutations of JAK2, CALR and MPL genes have 
been found in these diseases. However, these mutations do not allow the discrimination 
between the different diseases, being present in more than one form. World Health 
Organization (WHO) criteria, in fact, request in addition to the molecular study, a 
complete bone marrow histological evaluation. Pediatric ET is a rare disorder with an 
incidence about 60 times lower than the adult form albeit with similar blood finds. In 
children with ET, the incidence of JAK2V617F and CALR mutations is significantly 
lower than in adults, while hereditary cases characterized by MPL mutations are relatively 
more common. So far the histological evaluation of the bone marrow has not been 
exhaustively explored in this setting of patients. 
The aim of the present study was to evaluate the adequacy of current WHO criteria in 
pediatric ET exploring both the incidence of driver mutations and bone marrow features 
in a large cohort of children with a clinical diagnosis of ET. 
Our study was built in two steps: (i) a biomolecular study of a pediatric population with 
a clinical diagnosis of ET performed by Italian pediatricians, expert in hematological 
disorders and (ii) a histological evaluation strictly adherent to WHO criteria of BM 
features of a sub group of these children. Firstly, biomolecular studies of 89 children with 
a clinical diagnosis of ET, all having a sustained increase in platelet count (>450 x10^9/L) 
with no demonstrable reactive or secondary cause and no familial history of MPN or 
thrombocytosis, were evaluated to our central laboratory. In the second phase of our work 
we collected naïve bone marrow (BM) biopsies of 20 children with a clinical diagnosis 
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of ET (PedET) and, as controls, BM of 6 children (PedST) with reactive/secondary 
thrombocytosis, 18 children (Norm) with a normal BM histology and 36 adults (AdsET) 
with WHO-diagnosed ET. All BM biopsies were reviewed by two MPN’s expert 
pathologists, blinded to the cause of each child’s thrombocytosis. 
In the biomolecular study we found that 23 patients (25,8%) had a clonal disease. The 
JAK2V617F mutation was identiﬁed in 14 children, 1 child had the MPLW515L 
mutation, and 6 had CALR mutations. The HUMARA monoclonal X-chromosome 
inactivation pattern was demonstrate in 6 patients (two with JAK2V617F and two with 
CALR mutations). The other 66 patients (74,2%) had persistent thrombocytosis with no 
clonality. There were no clinical or hematological differences between the clonal and 
non-clonal patients. 
From the histological point of view, while cellularity was increased in all pediatric cases 
compared to adults (p<0.001), megakaryocytes (MK) density was higher in PedET (37.5 
MK/mm2) than in PedST (9.2 MK/mm2) (p<0.001). Moreover, MK clusters (100%) and 
BM fibrosis (30%) were observed only in PedET but not in PedST and in Norm.  The BM 
histology was similar in PedET and AdsET. On a whole, BM histology confirmed the 
diagnosis of ET in 15 children, suggested a PV in 1 child, a PMF in 3 (1 grade 1 and 2 
grade 0) and secondary thrombocytosis in one. 
Our study shows that children with ET are mostly non-clonal, however, the relative 
proportion of ET-speciﬁc mutations in the clonal children was much the same as in 
adults. Histological WHO criteria are able to identify ET, PMF and PV and distinguish 
ST from primary thrombocytosis, also in pediatric population. Therefore, WHO criteria 
seem suitable in all age groups, making both complete biomolecular evaluation and BM 
assessment mandatory in children with suspected ET. 
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RIASSUNTO 
Le Neoplasie Mieloproliferative (MPN), sono disordini clonali della cellula staminale 
emopoietica, caratterizzate dalla proliferazione di una o più linee mieloidi e sono 
Trombocitemia Essenziale (ET), Policitemia Vera (PV) e Mielofibrosi Idiopatica (PMF). 
I criteri diagnostici per le MPN dell’adulto si sono evoluti nel tempo di pari passo con 
l’acquisizione di nuove conoscenze clinico-laboratoristiche e biomolecolari di tali 
patologie. Negli ultimi anni sono state descritte mutazioni somatiche a carico dei geni 
JAK2, CALR e MPL, tuttavia queste mutazioni non consentono una distinzione accurata 
in quanto presenti in più di una MPN. Nei più recenti criteri diagnostici WHO, di 
conseguenza, accanto allo studio biomolecolare, è necessaria una completa valutazione 
della biopsia osteo-midollare (BOM). 
La ET pediatrica è una malattia rara con un’incidenza stimata di circa 60 volte inferiore 
alla forma dell’adulto. L’incidenza delle mutazioni di JAK2 e di CALR è 
significativamente inferiore nei bambini con ET rispetto agli adulti, mentre sono 
relativamente più numerosi i casi ereditari caratterizzati da mutazioni di MPL. Ad oggi in 
questi pazienti non è stata ancora esplorata esaustivamente la rilevanza della valutazione 
istologica del midollo. 
Lo scopo del nostro studio è stato quello di verificare l’adeguatezza dei criteri WHO nella 
popolazione pediatrica esplorando sia l'incidenza delle mutazioni principali che le 
caratteristiche della BOM in un'ampia casistica di bambini con diagnosi clinica di ET. 
Il nostro lavoro è stato costruito in due momenti: (i) uno studio biomolecolare in bambini 
con diagnosi clinica di ET fatta da Pediatri Italiani esperti in disordini ematologici e (ii) 
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una valutazione istologica della BOM in un sottogruppo di questi bambini, applicando 
rigorosamente i criteri WHO. 
Nella prima parte dello studio abbiamo valutato 89 bambini con diagnosi clinica di ET 
con un incremento prolungato della conta piastrinica (>450 x10^9/L) in assenza di cause 
secondarie o reattive e senza familiarità per MPN o trombocitosi. I campioni stati sono 
stati centralizzati presso il nostro laboratorio per lo studio biomolecolare completo. Nella 
seconda fase, abbiamo collezionato le BOM di 20 bambini con diagnosi clinica di ET 
(PedET) e, come controlli, di 6 bambini con trombocitosi reattiva (PedST), 18 bambini 
(Norm) con istologia midollare nella norma e 36 adulti con diagnosi di ET in accordo con 
in criteri WHO (AdsET). Tutte le BOM sono state rilette in cieco da due patologi esperti 
in MPN. 
Nello studio biomolecolare in 23 pazienti (25,8%) è stata dimostrata la presenza di un 
marker di clonalità: 14 bambini erano positivi per la mutazione JAK2V617F, 1 bambino 
aveva la mutazione MPLW515L e 6 avevano mutazioni di CALR. Inoltre, sei pazienti 
sono risultate clonali allo studio dell’inattivazione del cromosoma X (due portatrici anche 
la mutazione JAK2V617F e due con mutazioni di CALR). Gli altri 66 pazienti (74,2%) 
presentavano una trombocitosi persistente senza evidenza di clonalità. Non sono state 
dimostrate differenze clinico-ematologiche tra i pazienti clonali e non clonali. 
Dal punto di vista istologico, la cellularità è risultata più alta in tutti i casi pediatrici 
rispetto agli adulti (p <0.001), mentre la densità megacariocitaria (MK) è risultata più alta 
nei PedET (37,5 MK/mm2) rispetto a PedST (9.2 MK/mm2) (p <0,001). Inoltre, i cluster 
di MK (100%) e la fibrosi midollare (30%) sono stati osservati solo in PedET, essendo 
sostanzialmente assenti sia in PedST che Norm. L’istologia della BOM è risultata 
pressoché sovrapponibile in PedET e AdsET. Tra i bambini con PedET, l’istologia della 
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BOM ha confermato in 15 casi la diagnosi di ET, in 1 caso è risultata suggestiva per PV, 
in 3 casi per PMF (1 grado 1 e 2 grado 0) ed in un caso per trombocitosi secondaria. 
Il nostro studio conferma che, sebbene la maggior parte dei bambini non presenti un 
marker di clonalità, le mutazioni classiche delle MPN sono presenti anche nella ET 
pediatrica con una proporzione simile a quella delle forme dell’adulto. I criteri istologici 
WHO sono in grado, anche nella popolazione pediatrica, di identificare ET, PV e PMF e 
di distinguere forme primitive e secondarie di trombocitosi. 
In conclusione, i criteri WHO sembrano adeguati per tutte le fasce d’età. Ciò impone una 
completa valutazione biomolecolare ed istologica anche nei bambini con sospetta ET. 
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BACKGROUND 
Myeloproliferative Neoplasms (MPN) are clonal disorders of the hematopoietic stem cell 
characterized by proliferation of one or more myeloid lineages (granulocytic, erythroid, 
megakaryocytic), and consequent increase of red cell mass, leukocytosis and/or 
thrombocytosis. 
In 1951, William Dameshek first defined “Myeloproliferative Disorders” (MPD) (1), 
grouping in this category Chronic Myeloid Leukemia (CML), Polycythemia Vera (PV), 
previously known as Osler-Vasquez disease, Essential Thrombocythemia (ET), Primary 
Myelofibrosis (PMF) and Di-Guglielmo disease (erythroleukemia); the latter one has 
been then re-defined as acute erythroid leukemia and consequently excluded from MPNs 
(2).  
In 1960, Nowell and Hungerford discovered the Philadelphia Chromosome (Ph1) in 
Chronic Myeloid Leukemia (CML)(3). This chromosome is the result of a mutual 
translocation of chromosome 9 to 22 leading to the constitution of BCR-ABL1 fusion 
gene, that encodes for a protein with tyrosin-kinase activity (4,5).  Therefore, MPN were 
distinguished in Ph-1 positive and negative forms, the latter including PV, ET and PMF, 
then known as “Classic” Ph-1 negative myeloproliferative diseases (CMPDs) (6). 
MPN diagnostic criteria have been repeatedly updated along time. Louis Wasserman in 
1967 created the Polycythemia Vera Study Group (PVSG) that proposed diagnostic 
criteria for PV (7) and in 1986 those for ET, all based on the exclusion of mechanisms 
able to sustain clinical-laboratory findings. For instance, in ET, diagnosis implied absence 
of evidence for reactive thrombocytosis and exclusion of the other myeloid malignancies 
(8). 
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In 2001, the World Health Organization (WHO) released a new classification of 
myeloproliferative neoplasms (9), introducing histopathological features in bone marrow 
biopsy (BM) able to discriminate among different forms of MPN. For the first time in this 
classification early/prefibrotic primary myelofibrosis (pre-PMF) was considered. Patients 
labeled with pre-PMF are clinically undistinguishable from those with ET, but they have 
a different prognosis histologically based (10-11) (Figures 1,2). However, some Authors 
(12) claim that current histologic criteria are not sufficient to permit routine separation of 
ET into biologically distinct subsets. 
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Figure 1. Histologic characteristics of megakaryocytes (MK) of ET and pre-PMF. ET is characterized by 
loose clusters of MK (a), staghorn MK (b) or normal MK (c). Pre-PMF is characterized by tight cluster of 
MK (d) and bulbous MK (e). (pictures from our archives) 
 
ET      pre-PMF 
a.       d. 
  
 
b.       e. 
  
 
c. 
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Figure 2. BM grading of fibrosis. (pictures from our archives) 
 
Grade 0      Grade 1 
  
Grade 2      Grade 3 
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The clinical relevance of a correct evaluation of BM histology and morphology was 
later determined: in fact, it has been shown that pre-PMF patients display lower overall 
survival and higher rate of progression into overt myelofibrosis compared to “true” ET 
(Figure 3) (13). 
 
Figure 3. Survival estimates for patients with ET and pre-PMF were compared with those obtained by 
applying the 2008 Eurostat age- and sex standardized incidence rates for all causes of death to the general 
population, using the indirect standardization procedure (13). 
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In April 2005 five different groups (14-18) demonstrated the presence of a somatic 
mutation in exon 14 of JAK2 gene located in 9p24 chromosome, causing the replacement 
of a Guanine with a Thymine and thus the encoding of Phenylalanine instead of a Valine 
in position 617 of JH2 domain of JAK2 protein (JAK2V617F). JAK2 protein is a tyrosine-
kinase implied in the hematopoiesis and the JAK2V617F mutation causes constitutive 
activation of JAK2 and transduction of the signal, particularly for STAT5/Bcl-xL 
pathway (Figure 4). 
 
Figure 4. Representation of JAK2V617F mutation and effects. 
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JAK2V617F mutation is detectable in 90% of PV and in 50-60% of ET and MF patients. 
Screening for this mutation became rapidly mandatory in MPN evaluation, making both 
the PVSG and the 2001-WHO criteria out of date (19). 
In 2006, a somatic point mutation in exon 10 of MPL (Myeloproliferative Leukemia 
Virus) gene in chromosome 1p34, encoding thrombopoietin (TPO) receptor, was 
described. This mutation is responsible for the substitution of Trp Leu or Lys or Ala 
(MPLW515L, K or A) in the  transmembrane domain of TPO receptor (TpoR), resulting 
in a gain-of-function and constitutive activation of JAK/STAT signaling pathway. These 
genetic abnormalities are found in 5-10% of PMF and 1-3% of ET cases (20,21).  
Another mutation in MPL gene, resulting in substitution of SerAsn in codon 505 
(MPLS505N), has been initially identified in familial thrombocytosis, and then 
demonstrated in sporadic cases of ET (22) (Figure 5). 
 
Figure 5. Representation of c-MPL and its mutations. 
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In 2008, WHO published the new classification of MPN: CMPDs are renamed as 
myeloproliferative neoplasms, underlying the clonal origin of these diseases (23), as yet 
demonstrated by Adamson and Fialkow (24,25), and the presence/absence of 
biomolecular markers was included as a major criterion for diagnosis of MPN (26). 
In 2013, novel mutations in exon 9 of calreticulin (CALR) gene (27,28) have been 
described in 15% of ET and PMF. CALR gene encodes for a cytoplasmic protein of 
endoplasmic reticulum. The CALR mutations cause a frameshift to alternative reading 
frames: the resulting mutant CALR proteins share a novel amino acid sequence at the C-
terminal that contains a number of positively charged amino acids, whereas the non-
mutant CALR C-terminal is largely negatively charged (27). There are two types of CALR 
mutations: type 1 is a 52-bp deletion that results in loss of most of all negative charged 
amino acids; type 2 is a 5-bp insertion that maintains about 50% of normal amino acid 
sequence in C-terminal (28). Type 1 and 2 together represent about 80% of identified 
CALR mutations, the other 20% are rarer mutations. 
It has been recently demonstrated that the two most common MPN-associated CALR 
mutants induce constitutive, ligand-independent activation of TpoR: the interaction 
between CALR mutants and TpoR directly leads to close dimerization of JAK2 kinase 
domain and its activation. The extracellular domain of TpoR is crucial for activation by 
CALR mutants but their way of interaction is not yet exactly known. (29). It has been 
shown how TpoR is able to signal from several dimeric interfaces. It has been supposed 
that CALR mutant might stabilize one of the many active interfaces of TpoR (30,31), 
resulting in a constitutive activation of the receptor. Both CALR mutants (del52 and ins5) 
might stabilize two related, but not identical, active dimeric interfaces of TpoR, leading 
15 
 
to differences in the phenotype, as suggested (32, 3). Furthermore, binding of CALR 
mutant to TpoR and its activation do not require TPO-binding. 
 
Figure 6. Representation of CALR gene and locus of mutations. 
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The newly identified molecular features have yielded new perspectives regarding 
diagnostic and prognostic markers that provide novel insights for the understanding of 
MPN. Furthermore, the improved characterization and standardization of morphological 
and histological features have increased the reliability and reproducibility of diagnoses, 
aiding in the differentiation of these diseases. Therefore, in May 2016, a new revision of 
WHO criteria based on an integrated approach that includes hematologic, morphologic, 
cytogenetic and molecular genetic findings has been released and for the first time pre-
PMF has been described as an apart entity (Table I-IV) (34). 
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Table I. WHO-2016 criteria for PV (34). 
MAJOR 
CRITERIA 
1 
Hemoglobin > 16,5 g/dl (men), > 16,0 g/dl (women), or 
Hematocrit > 49% (men), > 48% (women), or 
increased red cell mass more than 25% above mean normal 
predicted value 
2 
BM biopsy showing hypercellularity for age with trilineage growth 
(panmyelosis) including prominent erythroid, granulocytic, and 
megakaryocytic proliferation with pleomorphic, mature 
megakaryocytes (differences in size) 
3 Presence of JAK2V617F or JAK2 exon 12 mutation 
MINOR 
CRITERION 
1 Subnormal serum erythropoietin level 
Diagnosis of PV requires meeting either all 3 major criteria, or the first 2 major criteria 
and the minor criterion 
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Table II. WHO-2016 criteria for ET (34). 
MAJOR 
CRITERIA 
1 Platelet count ≥ 450 x10^9/L 
2 
BM biopsy showing proliferation mainly of the megakaryocyte lineage 
with increased numbers of enlarged, mature megakaryocytes with 
hyperlobulated nuclei. No significant increase or left shift in neutrophil 
granulopoiesis or erythropoiesis and very rarely minor (grade 1) 
increase in reticulin fibers 
3 
Not meeting WHO criteria for BCR-ABL1+ CML, PV, PMF, 
myelodysplastic syndromes, or other myeloid neoplasms 
4 Presence of JAK2, CALR, or MPL mutation 
 
MINOR 
CRITERION 
1 
Presence of a clonal marker or absence of evidence for reactive 
thrombocytosis 
Diagnosis of ET requires meeting all 4 major criteria or the first 3 major criteria and the minor 
criterion 
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Table III. WHO 2016 criteria for pre-PMF (34). 
MAJOR 
CRITERIA 
1 
Megakaryocytic proliferation and atypia, without reticulin fibrosis > grade 
1, accompanied by increased age-adjusted BM cellularity, granulocytic 
proliferation, and often decreased erythropoiesis 
2 
Not meeting the WHO criteria for BCR-ABL1+ CML, PV, ET, 
myelodysplastic syndromes, or other myeloid neoplasms 
3 
Presence of JAK2, CALR, or MPL mutation or in the absence of these 
mutations, presence of another clonal marker,† or absence of minor 
reactive BM reticulin fibrosis 
MINOR 
CRITERIA 
Presence of at least 1 of the following, confirmed in 2 consecutive 
determinations: 
1 Anemia not attributed to a comorbid condition 
2 Leukocytosis ≥ 11 x10^9/L 
3 Palpable splenomegaly 
4 
LDH increased to above upper normal limit of institutional reference 
range 
Diagnosis of pre-PMF requires meeting all 3 major criteria, and at least 1 minor criterion 
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Table IV. WHO 2016 criteria for overt PMF (34). 
MAJOR 
CRITERIA 
1 
Presence of megakaryocytic proliferation and atypia, accompanied by 
either reticulin and/or collagen fibrosis grades 2 or 3 
2 
Not meeting WHO criteria for ET, PV, BCR-ABL1+ CML, myelodysplastic 
syndromes, or other myeloid neoplasms 
3 
Presence of JAK2, CALR, or MPL mutation or in the absence of these 
mutations, presence of another clonal marker, or absence of reactive 
myelofibrosis 
MINOR 
CRITERIA 
Presence of at least 1 of the following, confirmed in 2 consecutive 
determinations 
1 Anemia not attributed to a comorbid condition 
2 Leukocytosis ≥ 11 x10^9/L 
3 Palpable splenomegaly 
4 
LDH increased to above upper normal limit of institutional reference 
range 
5 Leukoerythroblastosis 
Diagnosis of overt PMF requires meeting all 3 major criteria, and at least 1 minor criterion 
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MPN are typical diseases of middle-advanced age, with a median age at diagnosis of 60-
65 years; they can affect both sexes, with a mild prevalence of males with PV and of 
females with ET (35). In 10-20% of cases, diagnosis occurs before age of 40 (36). 
These diseases are very rare in children and adolescents. 
While a reactive/secondary thrombocytosis is a common finding in pediatric age, 
especially in younger children, either because of the immaturity of their innate and/or 
adaptive immunity, or because they have more frequently infections (37), ET, despite 
being the most represented MPN in children, is uncommon. Under the age of 14, ET has 
an estimated incidence of 1/10 000 000 children/year (38), about 100x less than that of 
adults (39). It is also important to remember that familial ET is responsible in many 
pediatric cases, as seen in a large Italian series (40). PV has only been reported 
anecdotally in pediatrics and is possibly observed in teenagers or young adults (40). 
Due to the rarity of ET in pediatric age, few is known about the disease in this setting of 
patients. However, in the recent years some papers were published regarding ET in 
children. Unlike in adults, the majority of children with a clinical diagnosis of ET do not 
have clonal markers and seem to have different biological characteristics from adult cases 
(41). Varying frequencies of the JAK2V617F mutation have been reported in childhood 
ET, ranging from 0% to 30%, representing in any case an incidence lower than in adults 
(40-48). Interestingly, in a study of Veselovska et al. (47) within 5 children with ET and 
growth of erythrocytes (EEC) and granulocytes (CFU-GM) spontaneous colonies, while 
JAK2V617F mutation was undetectable in peripheral blood, it was present in two cases 
in EEC and in one in CFU-GM. This observation suggests that the inability to detect the 
JAK2V617F mutation in purified cell populations may be due to the rarity of JAK2V617F 
sub-clones, with an allele burden below the level of PCR detection limits. Therefore, the 
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incidence of the JAK2V617F mutation might be underestimated in children (47). The 
observed differences in clinical and hematological features between adults with or 
without JAK2 mutation and the several correlations of MPN phenotype with the 
JAK2V617F allele burden have not been confirmed in children (40,49). 
The MPL mutations are anecdotal in children with ET: on my best knowledge, there are 
only two published cases of pediatric non-familial ET patients carrying a MPL mutation 
(50,51), while in hereditary thrombocytosis MPL mutations (especially in position 505) 
are not rare (52,53). 
In a recent paper, Giona et al. describes CALR mutations in 44% of JAK2 and MPL wild-
type patients and 23% of all series in a cohort of ET patients younger than 20 years (54). 
Furthermore, CARL-mutated children were more frequently asymptomatic at diagnosis in 
comparison with those carrying JAK2V617F mutation (54). In contrast, Langabeer et al. 
failed to detect CALR mutations in a small series of ET patients younger than 15 years 
(55). On the whole, pediatric patients with a clinical diagnosis of ET, i.e. a sustained and 
prolonged increase in platelet count without any identifiable cause of thrombocytosis, 
seem to carry fewer driver mutations than adults. 
Therefore, the WHO criteria appear not adequate in children with clinical ET (44), but so 
far there is a lack of information regarding bone marrow (BM) histology in these patients 
(40,56). Pediatricians are reluctant to perform BM biopsy in the absence of a defined 
malignancy in children because it requires profound sedation. 
  
23 
 
AIM 
The aim of our study was to validate current WHO criteria in pediatric ET (i) exploring 
the incidence of driver mutations in a wide cohort of pediatric patients with ET (ii) and 
evaluating the BM histological features in children with a clinical diagnosis of ET. 
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MATERIALS & METHODS 
Our study was built in two stages: (i) a biomolecular study aimed to evaluate the 
prevalence of driver mutations in the pediatric population with a clinical diagnosis of ET 
and (ii) a histological study for the evaluation of BM features in pediatric ET in 
comparison both to adults affected by ET, strictly diagnosed in agreement with WHO 
criteria, and to pediatric ad-hoc collected controls. 
The Ethical Committee of Padua Hospital approved the study, an informed consent was 
obtained from each patient and controls. Children’s parents gave also their informed 
consent for their babies. The procedures adopted for the study were according to the 
Helsinki Declaration.  
 
Biomolecular Study 
We collected 89 children (58 females and 31 males) with a clinical diagnosis of ET 
established at one of the 14 tertiary hematology centers linked to the Italian Pediatric 
Hemato-Oncology Association (AIEOP), which were consecutively referred to our 
central laboratory in Padua for bio-molecular studies, who were younger than 18 years 
old at the time of their diagnosis of ET (median age 8,7 years, range 6 months to 16,5 
years), with a median follow-up of 6,3 years (range 1–19 years). All the children had a 
sustained increase in platelet count (>450 x10^9/L) lasting at least 12 months, with no 
demonstrable reactive or secondary cause (i.e. iron deficiency, acute or chronic 
inflammation, autoimmune diseases, Kawasaki syndrome, asplenia, neoplastic diseases 
or any medication), and no familial history of MPN or thrombocytosis. None of the 
children met the WHO criteria for other myeloid neoplasms. 
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The research of mutations was conducted on genomic DNA extracted from granulocytes 
of peripheral blood sample, separated through Ficoll-Paque Plus solution. (42) 
The JAK2V617F mutation was genotyped using allele-speciﬁc polymerase chain reaction 
(PCR) and the mutant allele burden was measured by quantitative real-time PCR (42,49). 
The MPL and CALR mutations were sought by direct sequencing (27,57). The X-
chromosome inactivation pattern (X-CIP) in granulocytes was studied in females using 
the human androgen receptor gene (AR, also termed HUMARA) polymorphism method, 
as reported in literature (42). 
An ad-hoc spreadsheet was built to collect several parameters at diagnosis and during 
follow-up, including main clinical characteristics, blood counts and vascular events 
(Figure 7). 
 
Figure 7. Collected data. 
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Histological Study 
For the histological study, we collected all the treatment-naïve BM specimens (prepared 
in hematoxylin-eosin staining and silver impregnation after Gomori or Gordon-Sweet) of 
children with a clinical diagnosis of ET (PedET; 7 females and 13 males) available in 
AIEOP centers. Almost all of them are also included in the biomolecular study. The 
diagnosis of ET (PedET) was performed by a Pediatrician expert in hematology and based 
on the WHO criteria. The BM biopsies were initially analyzed by local pathologists, 
therefore centralized and then reviewed by two expert pathologists according to WHO 
histologic criteria, first separately and then jointly. 
Assessed parameters were: 
1. Cellularity (defined as ratio between hematopoietic marrow and adipose tissue) 
2. Myeloid-to-erythroid ratio 
3. Myeloid and erythroid maturation 
4. Megakaryocyte (MK) number and morphology 
5. Presence of loose or tight MK clusters 
6. MK density (MKD = number of MK per square millimeter of BM) 
7. Grade of fibrosis 
The pathologists were blinded to each child’s clinical and molecular diagnosis. 
As controls we evaluated BM specimens of: 
- 6 children (PedST; 4 females and 2 males) with reactive/secondary 
thrombocytosis: 5 had lymphomas and BM biopsy was performed as part of the 
staging process; one had a prolonged thrombocytosis >650 x10^9/L that resolved 
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spontaneously after 1 year. All tested cases were negative for JAK2, MPL or CALR 
mutations. 
- 18 children (Norm; 5 females and 13 males) with a normal BM histology, 
performed for the staging of solid tumors; none of them had splenomegaly and all 
had normal platelets number. 
- 36 adults (AdsET, 26 females and 10 males) with ET diagnosed strictly according 
to the WHO criteria. 
Main clinical characteristic of patients and controls enrolled in the histological study are 
resumed in Table V. 
 
Table V. Characteristics of patients and controls. 
 
PedET 
n=20 
PedST 
n=6 
AdsET 
n=36 
Norm 
n=18 
Median age at diagnosis/ BM 
Biopsy (percentile 5-95th) 
10 
(5.1 – 16.1) 
7.8 
(2.6 – 10.7) 
51.8 
(28.7 – 79.8) 
10.5 
(2 – 16) 
Males, n (%) 13 (65) 2 (33.3) 10 (27.8) 13 (72.2) 
Hb, g/L 
Median (percentile 5-95th) 
132 
(113 – 141) 
113 
(73 – 125) 
135 
(109 – 155) 
129 
(106 – 160) 
Ht, % 
Median (percentile 5-95th) 
40 
(37.4 – 43.3) 
37 
(23.3 – 38.8) 
41.4 
(34.4 – 47.8) 
39.1 
(30 – 47.5) 
WBC, x 10^9/L 
Median (percentile 5-95th) 
8.2 
(5.5 – 11.8) 
9.1 
(7 – 10.6) 
7.9 
(4.7 – 11.1) 
7.6 
(4 – 15.5) 
Plts, x 10^9/L 
Median (percentile 5-95th) 
1254 
(528 – 1824) 
502 
(478 – 657) 
681 
(487 – 1117) 
296 
(195 – 375) 
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Statistical analysis  
All statistical analyses were performed on the parameters recorded at the time of a 
patient’s diagnosis. Nominal variables were compared with the X 2 or Fisher’s exact tests, 
as appropriate. Continuous variables were compared with the T-test or the Mann-Whitney 
U test when indicate. A two-tailed P value of less than 0.05 was considered significant. 
All statistical analyses were performed using the SPSS (Statsoft Inc., Tulsa, OK, USA) 
software v.23. 
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RESULTS 
Biomolecular Study 
In this study we evaluate 89 subjects.  
Out of the 89 evaluated JAK2V617F mutation was found in 14 children (15,7%), with an 
allele burden of 26,26 ± 9,78%, the MPLW515L mutation in 1 and CALR mutations in 6 
(8%; 4 had CALR type 1 and 2 had CALR type 2) cases. None of the patients had more 
than one mutation. In contrast, 68 children (76,4%) were triple negative (3NEG). 
Clonality assays were available for 21 girls: 6 (28,5%) were found monoclonal, and 4 of 
them carried JAK2V617F or CALR mutations, while 2 were 3NEG (Figure 8). The main 
clinical ﬁndings divided by clonal and non-clonal patients are summarized in Table VI. 
 
Figure 8. Molecular findings. Among CALR mutated patients 4 were type 1 and 2 were type 2. 
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Table VI. Main clinical and laboratory characteristics at diagnosis of the 89 patients divided by clonal and 
non-clonal. 
 Clonal Non Clonal P 
Patients, n (%) 23 (25,8) 66 (74,2)  
Males/females  8/15 23/43 NS 
Median age, years (range) 10,25 (0,5-17,5) 8,3 (0,5-16,5) NS 
Age cut-off   NS 
<11 years, n 14 46 - 
<15 years, n 20 59 - 
15–18 years, n  3 7 - 
Median follow-up, 
years (range) 
7,55 (1-11,5) 6,14 (1-20) NS 
Driver mutations   - 
JAK2V617F, n 14 0 - 
JAK2V617F Allele burden, % 
(mean ± SD) 
26,26 ± 9,78 - - 
MPLW515L, n 
(56 tested) 
1 0 - 
CALR mutations, n 
(74 testes) 
6 0 - 
X-CIP positive 
(23 females tested) 
6 
(2 JAK2V617F; 2 CALR) 
0 - 
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Table VI (continue). Main clinical and laboratory characteristics of the 89 patients divided by clonal and 
non-clonal. 
 Clonal Non Clonal P 
Major thrombotic events 
 
 
 
3 (13) 
 
2 Budd Chiari Syndrome 
1 Cerebral vein Thrombosis 
0 
 
 
 
0.03 
 
 
 
Minor bleeding episodes  3 (13) 5 (7,5) NS 
Patients with microvascular 
disturbances  
8 (34,7) 19 (28,8) NS 
Headache  5 18 - 
Paraesthesia  2 7 - 
Erythromelalgia  2 1 - 
Palpatory splenomegaly, n 
(%) 
9 (39,1) 17 (25,7) NS 
Median platelet count, 
x10^9/L (range) 
1192 (512-3200) 1239 (503-4440) NS 
Median WBC count, 
x10^9/L (range) 
8,94 (5,5-11,8) 9,02 (5,25-19) NS 
Mean Hb level, 
g/L (range) 
138 (105-160) 125 (80-148) NS 
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Three different age groups were analyzed: younger children (less than 11 years old), 
young adolescents (up to 15 years old) and older adolescents (15–18 years old). No 
differences of the distribution of clonal versus non-clonal cases emerged when we divided 
the children in three groups of age (Table VI). 
Main clinical and laboratory findings of patients with a clonal marker are summarized in 
Table VII.  
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Table VII.  characteristics of the patients grouped by molecular marker. 
 JAK2V716F MPL CALR Monoclonal 
Patients, n 14 1 6 2 
Males/females  6/8 1/10 1/5 0/2 
Median age, 
Years (range) 
10,5 (2,5-17,5) 5,05 12,7 (7,9-13,9) 4,1 (0,5-7,5) 
Median follow-up, 
Years (range) 
8 (5-9) 3 6,2 (5,4-11,45) 6,55-9 
X-CIP positive/studied 2/8 - 2/4 2/2 
Major thrombotic 
events, n 
3 0 0 0 
Minor bleeding 
episodes, n 
1 0 2 0 
Patients with 
microvascular 
disturbances, n 
3 1 4 0 
Headache, n 3 0 2 0 
Paresthesia, n 0 0 2 0 
Erythromelalgia, n 0 1 1 0 
Splenomegaly Y/N 6/4 0/1 2/4 1/1 
Median platelet count, 
x10^9/L (range) 
1042 (512-1710) 1444 1424 (748-3200) 1223-1553 
Median WBC count, 
x10^9/L (range) 
9,1 (5,5-11,8) 9,6 10,1 (6,6-16,5) 6,9-7,5 
Mean Hb level, g/L 
(range) 
137 (111-157) 113 122 (105-160) 125-144 
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No statistically significant difference was seen comparing sex distribution, white blood 
cells and platelets count between JAK2 positive and CALR positive patients (p =NS). 
Hemoglobin levels show a tendency, not statistically significant, to be higher in JAK2 
compared to CALR positive patients (p=0.054). 
Three children presented with major thromboses (two Budd–Chiari syndromes and one 
cerebral vein thrombosis) and they all carried the JAK2V617F mutation. Minor 
hemorrhages occurred in one child with the JAK2V617F mutation and in two with a 
CALR mutation. Three JAK2-mutated, four CALR-mutated patients and the one with the 
MPL mutation had microvascular symptoms, mainly headache (Table VII). 
Data on the administered treatments were available for 19 clonal and 51 non-clonal cases 
(Table VIII). 
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Table VIII. Treatment administration in clonal and non-clonal cases. 
 
Clonal 
(N=23) 
Non-Clonal 
(N=66) 
Patients with available data  19 51 
No treatment  3 (15,8%) 12 (23,5%) 
Aspirin  11 (57,9%) 32 (62,7%) 
LMWH/Warfarin  3 (15,8%) 0 
Cytoreductive drugs  13 (68,4%) 20 (39,2%) 
ANA  6 8 
IFN  0 2 
HC  4 4 
Multiple cytoreductive drugs*  3 6 
 
LMWH, low molecular weight heparin; IFN, interferon alpha; HC, hydroxycarbamide; ANA, 
anagrelide. 
*Six patients were given ANA + HC, one ANA + IFN and two were given HC + ANA + IFN. 
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Antiplatelet and anticoagulant drugs were commonly used in combination with 
cytoreductive treatments. In the clonal group, 3 children (15,8%) received no treatment, 
11 were given low-dose aspirin (acetylsalicylic acid, ASA), 3 anticoagulant therapy, and 
13 (68,8%) received cytoreductive drugs [hydroxycarbamide (HC) in 36,4%, anagrelide 
(ANA) in 47,3% and interferon-alpha (IFN) in 5,2%]. Three of these 13 patients (15,8%) 
received multiple cytoreductive drugs (2 ANA plus HC; 1 ANA plus IFN and HC). 
Twelve (23,5%) patients in the non-clonal group were never treated while 32 (62,7%) 
received ASA, 20 (39,2%) cytoreductive drugs (8 ANA, 4 HC, 2 IFN), and 6 (11,7%) had 
multiple cytoreductive drugs. (Table VIII). 
Six children had persistently high platelet counts (over 1000 x10^9/L) for many years: 
four of them received low dose ASA, two were given IFN (for 1 and 2 years), and one 
girl was treated for less than a year with ANA. Surprisingly, the platelet counts in these 
patients became normal over the course of a long-term follow-up (median 15 years, range 
5– 20) without cytoreductive drugs. 
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Histological Study 
The main clinical and laboratory data of the children with ET or ST and of adults with 
ET are summarized in Table IX. 
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Table IX. Clinical and laboratory features of children with ET (PedET), adults with ET (AdsET), children 
with secondary/reactive thrombocytosis (PedST) and comparison between PedET and AdsET. 
 PedET AdsET 
P 
PedET vs AdsET 
PedST 
Nr. of patients 20 36 - 6 
Median age at diagnosis, 
Y (5th-95th percentile) 
10 
(5.1 – 16.1) 
51.8 
(28.7 – 79.8) 
- 
7.8 
(2.6 – 10.7) 
Median follow-up, Y 
(5th-95th percentile) 
4.6 
(0.5 – 10.9) 
10 
(0.5 – 19.3) 
- - 
Splenomegaly, n (%) 11 (55) 7 (19.4) 0.017 1 (16.7) 
MVD, n (%) 8 (40) 8 (22.2) NS 1 (16.7) 
Abdominal pain, n (%) 4 (20) 0 (0) 0.005 0 (0) 
Thrombosis, n (%) 3 (15) 8 (22.2) NS 0 (0) 
Hemorrhage, n (%) 2 (10) 7 (19.4) NS 0 (0) 
Median Hb, g/L 
(5th-95th percentile) 
132 
(113 – 141) 
135 
(109 – 155) 
NS 
113 
(73 – 125) 
Median Ht, % 
(5th-95th percentile) 
40 
(37.4 – 43.3) 
41.4 
(34.4 – 47.8) 
NS 
37 
(23.3 – 38.8) 
Median WBC, x 10^9/L 
(5th-95th percentile) 
8.2 
(5.5 – 11.8) 
7.9 
(4.7 – 11.1) 
NS 
9.1 
(7 – 10.6) 
Median Plts, x 10^9/L 
(5th-95th percentile) 
1254 
(528 – 1824) 
681 
(487 – 1117) 
0.001 
502 
(478 – 657) 
JAK2V627F, n (%) 5 (25) 14 (38.9) NS 0 (0) 
CALR, n (%) 2 (10) 9 (25) NS 0 (0) 
MPLW515L, n (%) 1 (5) 2 (5.5) NS 0 (0) 
3NEG, n (%) 12 (60) 11 (30.5) NS 6 (100) 
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Splenomegaly was found more often in children than in adults (PedET vs AdsET 
p=0.017), and abdominal pain was only reported in pediatric age (PedET vs AdsET 
p=0.005). No significant differences were found between the PedET and AdsET cases in 
terms of MVD, major thrombosis or hemorrhage. Median platelet count differed 
significantly, being higher in children than in adults (PedET vs AdsET p=0.001; Table 
IX). 
Among children with ET, JAK2V617F mutation was detectable in 25% of cases, 10% 
carried a CALR mutation (one type 1 and one type 2), 1 was MPL positive and the 
remaining 60% was 3NEG (Figure 9). Comparison between histological features of 
children with ET and controls are summarized in Table X. 
 
Figure 9. Distribution of MPN driver mutations in children with ET. 
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Table X. Comparison between histological findings of study groups. 
 
PedET (A) 
n=20 
PedST (B) 
n=6 
P 
A vs B 
AdsET (C) 
n=36 
P 
A vs C 
Norm (D) 
n=18 
P 
A vs D 
Cellularity, % 
Median (percentile 5-95th) 
80 
(35 – 95) 
80 
(50-80) 
ns 
35 
(20 – 80) 
<0.001 
65 
(50-90) 
ns 
MK morphologic 
alterations, n (%) 
17 (85) 0 (0%) <0.001 36 (100%) ns 0 (0%) <0.001 
MKD, MK/mm^2 
Median (percentile 5-95th) 
37.5 
(10.5 – 107.1) 
9.2 
(5.6-13.6) 
<0.001 
18.3 
(9.4 – 55.2) 
<0.001 
10.4 
(2.2-14.0) 
<0.001 
MKD/cellularity, 
Median (percentile 5-95th) 
46.6 
(12.7-133.9) 
15.6 
(11.2-19.4) 
<0.001 
45.8 
(15.2-105.4) 
ns 
15.0 
(3.1-22.3) 
<0.001 
Presence of MK clusters, 
n (%) 
20 (100) 0 <0.001 36 (100) ns 0 <0.001 
Presence of dense MK 
clusters, n (%) 
3 0  0  6  
Presence of BM fibrosis, 
n (%) 
6 (30) 0 ns 6 (16.7) ns 3 (17%) ns 
  
MK= megakaryocytes; MKD= megakaryocytes density
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Cellularity was higher in all pediatric cases than in adults (p<0.001). Children with PedET 
were characterized by a higher MKD (37.5 MK/mm2) than those with PedST (9.2 
MK/mm2) (p<0.001), and by MK clusters (100%) and BM fibrosis (30%), which were 
substantially absent both in PedST and in Norm. 
All relevant pathological features of the BM biopsies were similar in PedET and AdsET. 
MKD was higher in PedET than in adult cases, but this difference disappeared when MK 
were normalized for BM cellularity. 
Table XI contains a detailed analysis of the 20 PedET cases. 
Three JAK2V617F (1M, 3F and 16F) children had a major thrombotic event (2 transient 
ischemic attacks and 1 Budd-Chiari syndrome). One child had BM features suggestive of 
PV, and one of PMF-1. All the other children with mutations exhibited a BM picture of 
true ET.  
Among the 3NEG children, two had a histology suggesting pre-PMF, with cloud-like MK 
in tight clusters but no BM fibrosis. In 10 other children, the histological pattern was 
consistent with ET, in agreement with the clinical picture. One 3NEG child had BM 
features of ST. 
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Table XI. Detailed analysis of the 20 PedET cases. 
Patient Clinical Molecular Histology 
1M 
TIA, headache, minor hemorrhage, 
occasional increase in HB and HT, 
splenomegaly 
JAK2 PV/ET 
2F 
Headache, erythromelalgia, minor 
hemorrhage, splenomegaly  
CALR type 1 ET 
3F 
Budd Chiari, portal thrombosis, OLT, 
splenomegaly 
JAK2 PMF-1 
4M Asymptomatic, splenomegaly CALR type 2 ET 
5M Erythromelalgia MPL ET 
6M Headache, splenomegaly JAK2 ET 
7M Headache, abdominal pain, splenomegaly 3NEG ET 
8F Headache, abdominal pain, splenomegaly 3NEG ET 
9M Asymptomatic, splenomegaly 3NEG Pre-PMF 
10F 
Headache, occasional increase in hemoglobin 
and hematocrit 
3NEG ET 
11M Headache, abdominal pain 3NEG ET 
12F Asymptomatic, splenomegaly 3NEG ET 
13M Abdominal pain 3NEG ET 
14F Asymptomatic 3NEG ET 
15M Asymptomatic 3NEG ET 
16F TIA, splenomegaly JAK2 ET 
17F Asymptomatic, splenomegaly 3NEG ST 
18M Asymptomatic 3NEG Pre-PMF 
19M Asymptomatic, splenomegaly JAK2 ET 
20M Asymptomatic 3NEG ET 
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DISCUSSION 
Myeloproliferative Neoplasms (MPN) are clonal disorders of the hematopoietic stem 
cells. MPN, in the most recent WHO classification, are those not carrying BCR/ABL1 
rearrangement (Philadelphia-negative) and are divided in classic (PV, ET, PMF) and rare 
(Chronic neutrophilic leukemia, Chronic eosinophilic leukemia not otherwise specified, 
MPN unclassifiable and Mastocytosis) (3,58) The discovery of JAK2V617F mutation, 
detectable in 90% of PV and about two-thirds of ET and PMF patients, led to the 
knowledge of a new relevant feature in diagnosis of MPN. However, the presence of the 
mutation alone cannot identify a specific MPN (59). This is true also for the more recent 
described mutations in the MPL and CALR genes (20,21,27) that are found both in ET 
and in PMF patients. Therefore, histological features of the BM are now considered 
necessary to distinguish PV, ET and PMF, mainly in patients with asymptomatic 
thrombocytosis without a specific clinical-biochemical profile (13). Today, a correct 
evaluation of the BM histology and morphology is a cornerstone in the diagnostic tool of 
patients with ET, because it can discriminate between pre-PMF and “true” ET. In the new 
WHO classification ET and pre-PMF are reported as two distinct MPN (34) because, in 
spite of an undistinguishable clinical phenotype, the prognosis of the two forms is 
different (13). 
The main clinical features of patients with MPN are thrombotic and hemorrhagic 
complications (60-64). Thromboses represent the major cause of morbidity and mortality 
but it must be taken into account that progression into myelofibrosis or transformation in 
acute leukemia occur respectively in 1.6 per 1000 pats/y and 1.2 per 1000 pats/y in ET 
and both in 5 per 1000 pats/y in PV (65,66). These transformations may occur as a natural 
evolution of the disease or may be due to the use of cytoreductive drugs (67-70).  
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Classical MPN are diseases typical of the median-advanced age, while they are 
uncommon in young adults and even more rare in adolescents and children (36,71), with 
an estimated annual incidence of newly-diagnosed cases around 1 per 10 million of 
children younger than 14 years (38). In contrast, thrombocytosis is a common finding in 
children (37), given that inflammatory diseases (i.e. upper respiratory inflammation, 
allergy, exanthematous diseases) are usual in pediatric age, both in hospital and in the 
outpatient setting (72). Such cases of reactive/secondary thrombocytosis (ST) relate to 
increased levels of cytokines, especially IL6 (37), and represent an inflammatory reaction 
carrying no thrombotic or hemorrhagic risk, destined to return to the normal 
spontaneously. Rare hereditary thrombocytoses have been described (57,73) as well.  
When a child shows prolonged and sustained thrombocytosis, this raises the question of 
whether it is a sign of chronic inflammation or an ET (74).  
Interestingly, pediatricians are rather reluctant to perform a complete workup for the 
diagnosis of ET comprehending BM biopsy, while they have extensive used 
cytoreductive drugs to obtain a normal platelet count (74-76).  Therefore, BM biopsy data 
in pediatric population with MPN are poor (40,56). 
Considering that most children with ET do not reveal clonal markers and that pediatric 
ET seem to have different biological characteristics from adults (41), even in the absence 
of histological BM data, the WHO criteria have been considered inadequate in children 
(45).   
In our biomolecular study, in agreement with the data of the literature (37,42,75) 
JAK2V617F mutation was found in less than one in four cases, and the MPLW515L 
mutation was only identiﬁed in one patient, recently described also elsewhere (50). We 
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found six children carrying CALR mutations: four were type 1 and two were type 2 (33). 
While a recent small study (55) detected no CALR mutations in six children with ET, 
other authors (54) found eight CALR-mutated children in their monocentric series of 34 
children. Given the relatively low sensitivity of sequencing for mutation detection 
purposes, low-level MPL and CALR mutants may go undetected (77, 41). While adult 
patients with JAK2V617F mutation are reportedly to be older, with a male prevalence, 
higher hemoglobin levels and white cell counts, and lower platelet counts than patients 
with CALR mutations (78), we found no such differences among our children. 
Major venous thromboses at unusual sites (involving the splanchnic veins) occurred in 
two children in the present cohort, all carrying JAK2V617F mutation (74). In the 
literature, among adults with JAK2V617F mutation, higher rates of venous thrombosis at 
uncommon sites have been reported in large cohorts (79,80). The risk of major thrombotic 
events has been described as low for CALR mutated adults (27,81-83), while our CALR-
mutated children suffered more often from mild bleeding and minor microvascular 
disturbances than their JAK2V617F-positive counterparts (though the difference was not 
statistically signiﬁcant). No other signiﬁcant differences were found when we compared 
patients with different mutations. 
On the whole, 23 of the 89 patients reported in the biomolecular study had clonal disease, 
while the other 66 had persistent thrombocytosis with no markers of clonality. No 
signiﬁcant differences in hematological and biological features has been demonstrated 
when we compared clonal versus non-clonal cases. The proportions of cases with clonal 
versus non-clonal disease were substantially the same for children and adolescents (84). 
Considering the mutated cases, the relative proportions of the three known ET-speciﬁc 
mutations in our sample (JAK2 vs. MPL vs. CALR: 60% vs. 4,3% vs. 26%) is like the 
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proportions found in adults (27,82), so pediatric clonal ET is presumably the same as the 
disease encountered in adults. 
Children with no clonal markers accounted for a large proportion of our sample. We 
observed a remarkably high difference of prevalence of non-clonal cases in our cohort in 
comparison to adult reports (74% vs. 10–15%) (78), and this did not vary when children 
were compared with adolescents (55). 
It is worth noting that we observed a “spontaneous remission” in two children with non-
reactive sustained thrombocytosis (about 2000 x10^9/L) over a period of more than 15 
years: they were both 3NEG cases and X-CIP-negative. Two of such cases had already 
been reported in the literature (85). In our series, four other girls with a non-clonal pattern 
have been followed up for more than 10 years now, and have not developed neither new 
mutations nor a monoclonal pattern. These observations may suggest that in some cases 
at least, a different non-clonal mechanism may underlie to megakaryocyte proliferation 
and excessive platelet production posing many questions also about the correct 
therapeutic approach (86,75). 
Considering that, while adult’s triple negative cases are still considered MPN because of 
a complete histologic study that fulfills the WHO criteria (34), our non-clonal children, 
in the absence of a BM histology, actually should not be deﬁnitively assumed to be MPN 
cases, even if presenting with a clinical picture suggestive of MPN (minor bleeding 
episodes, microvascular disturbances and splenomegaly).  
Therefore, in the second phase of the present work, we explore the histology of BM in 
children with a clinical diagnosis of ET to evaluate, also in this setting of patients, the 
well-known histologic characteristics, stated in the WHO criteria to perform a diagnosis 
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of MPN (10,34). We addressed this issue in 20 children whose BM biopsy performed at 
diagnosis were available in our collaborating centers. At present, the available data about 
BM histology in children with MPN are very limited. Giona et al (40) described 5 BM 
biopsies from children with primary familial thrombocythemia, which revealed 
histological features no different from those of children with sporadic thrombocythemia. 
Fu et al (41) reported 63 children with ET whose BM biopsy findings were “consistent 
with ET”. A detailed description of pediatric BM histology that meets Thiele’s 
requirements (10) has only been done by Roy (56) in a single patient, making our 20 
children cohort the largest with a complete depiction of BM features. 
Among our 20 children with clinical ET, our centralized histologic review identified 19 
BM morphologically consistent with a myeloproliferative neoplasm, corresponding to 15 
“true” ET, 1 PMF-1, 2 pre-PMF and 1 case more suggestive for PV; 1 child with 3NEG 
status had a histological picture of ST. In contrast, all 6 children with ST showed only a 
mild increase in MK number, in keeping with Thiele’s observation in adults with a 
secondary/reactive increase in platelet count (10). 
In this subset of patients, we found also a low incidence of driver mutations and about 
two-thirds of our children with clinical ET does not reveal a clonal marker, while the 
mutated cases, although few, seem to respect the known proportion of JAK2, CALR and 
MPL mutations (74). All but one of our 3NEG children had both clinical and histological 
features of ET. Irrespective of their mutational status, the children with a histologically 
confirmed diagnosis of ET had a picture similar to that of adult ET, although with a higher 
cellularity. Megakaryocytes density (MKD) (87) was higher in pediatric ET too, but when 
the MK number was normalized to cellularity (MKD/cellularity), we found a similar ratio 
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in children and adults. None pediatric control (PedST and Norm) displays MK 
abnormalities or MK clusters. 
The BM of one JAK2V617F boy was suggestive of PV. It has been recently described in 
adults carrying JAK2V617F mutation, a “new” nosological entity called “masked PV” 
(88), characterized by a mild increase of hemoglobin and hematocrit not meeting the 
required levels of WHO criteria for PV (39). Masked PV has higher risk of thrombosis 
(89) compared both to ET and to overt PV, it is more common in young males and can 
be associated with very high platelet count and mild marrow fibrosis (88). The sum of 
clinical and histological features seen in our case points to masked PV because the patient 
had an increase in the number of erythroid cells in the BM, a transient increase in 
hemoglobin and hematocrit (> 95th percentile for age), and a transient ischemic attack.  
One girl with JAK2V617F mutations, reported also in the biomolecular study, had Budd 
Chiari syndrome. She had a histological picture of PMF-1, with an increased number of 
MK with cloud-like nuclei, often arranged in tight clusters, and grade 1 fibrosis. Her 
clinical course was complicated, resembling PMF, and she underwent liver 
transplantation for hepatopulmonary syndrome, portal thrombosis, progressive 
splenomegaly and low peripheral cells counts. It is worth noting that the first BM biopsy 
was performed after12 years of follow-up. It is therefore not clear whether the histological 
findings are attributable to the primary MF or to an evolution of the ET. It is also worth 
emphasizing the evidence of other two 3NEG patients with a histologic picture of pre-
PMF, which supports the impression that PMF can occur in pediatric age, albeit very 
rarely (90). 
In one 3NEG child, our histology review identified features more suggestive of ST than 
of ET, reinforcing the hypothesis that several children with sustained and prolonged 
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thrombocytosis may not have a primitive disease (74). One PedST case was initially 
diagnosed clinically as ET, but his thrombocytosis resolved spontaneously within a year. 
His BM showed a histological picture of ST. On the whole, these experiences underline, 
in suspected ET cases, the importance of BM biopsies evaluation in MPN expert centers 
(91) taking in mind that not all pathologists agree with the reproducibility of Thiele’s 
criteria (Wilkins). 
The therapeutic goal for ET patients is to avoid the occurrence of major vascular events 
while minimizing the side effects induced by medicine. Consensus regarding the 
management of adult ET is a risk-adapted strategy (92). Low-dose aspirin is 
recommended in low risk ET patients, while in high-risk patients cytoreductive therapy 
should be added (93,94). 
The decision to start cytoreductive therapy in children with ET requires careful thought, 
bearing in mind not only the patients’ platelet counts but also their clinical, molecular and 
histological features (41,63,83), as in adults (93,94). There is insufﬁcient evidence to 
guide the management of childhood ET, but a conservative approach is recommended 
(40,74,76,95). 
In conclusion, our data clearly show that a complete workup for MPN diagnosis, 
comprehensive both of biomolecular and histological study, is fundamental in children 
with suspected MPN. Due to the low incidence of driver mutations, the complete 
biomolecular study is not sufficient to identify all MPN patients and cannot distinguish 
among different forms. Moreover, the clinical phenotype of children with non-clonal 
sustained thrombocytosis is identical to that of clonal ET and, even in case with long 
follow-up, it may not be able to discriminate between children with real 3NEG ET (78) 
and non-myeloproliferative patients. 
52 
 
Therefore, BM histology is mandatory to the diagnosis of MPN in children as in adults. 
A correct BM assessment can both discriminate among ET, PMF and PV, and distinguish 
secondary/reactive from primary thrombocytosis. An important question remains 
unanswered, however: how long should a 3NEG child with a high platelet count be kept 
under observation before performing a BM biopsy? National guidelines in Italy 
(unpublished data) suggest an interval of 6 to 12 months, depending on the platelet count. 
The present findings need to be confirmed. 
It has been repeatedly claimed that pediatric MPN need tailored diagnostic criteria 
(45,95). However, our data clearly demonstrate that the in-use WHO criteria for MPN are 
suitable in all age groups, being not only adequate, but also accurate even in pediatric 
population. 
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